Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.
2.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

3.

Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene.

Gong G, Whittemore AS.

Genet Epidemiol. 2003 Apr;24(3):173-80.

PMID:
12652521
4.

Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.

Tryggvadottir L, Sigvaldason H, Olafsdottir GH, Jonasson JG, Jonsson T, Tulinius H, Eyfjörd JE.

J Natl Cancer Inst. 2006 Jan 18;98(2):116-22.

PMID:
16418514
5.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

6.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.

Clin Cancer Res. 2008 May 1;14(9):2861-9. doi: 10.1158/1078-0432.CCR-07-4436.

7.

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members..

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.

8.

[Clinical and molecular diagnosis of inherited breast-ovarian cancer].

Chompret A.

J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. Review. French.

9.

Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.

Scott CL, Jenkins MA, Southey MC, Davis TA, Leary JA, Easton DF, Phillips KA, Hopper JL.

Hum Genet. 2003 May;112(5-6):542-51. Epub 2003 Feb 25.

PMID:
12601471
10.

Re: On the use of familial aggregation in population-based case probands for calculating penetrance.

Whittemore AS, Gong G.

J Natl Cancer Inst. 2003 Jan 1;95(1):76-7; author reply 77-8. No abstract available.

PMID:
12509408
11.

Re: On the use of familial aggregation in population-based case probands for calculating penetrance.

Burke W, Austin M.

J Natl Cancer Inst. 2003 Jan 1;95(1):78-9. No abstract available.

PMID:
12509410
12.

Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.

Fu R, Harris EL, Helfand M, Nelson HD.

Stat Med. 2007 Apr 15;26(8):1775-87.

PMID:
17243094
13.

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.

Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG.

Eur J Cancer. 2006 May;42(8):1143-50. Epub 2006 Apr 27.

PMID:
16644204
14.

Re: On the use of familial aggregation in population-based case probands for calculating penetrance.

Risch HA, Narod SA.

J Natl Cancer Inst. 2003 Jan 1;95(1):73-4; author reply 77-8. No abstract available.

PMID:
12509405
15.
16.

Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.

Anton-Culver H, Cohen PF, Gildea ME, Ziogas A.

Eur J Cancer. 2000 Jun;36(10):1200-8.

PMID:
10882857
17.

Re: On the use of familial aggregation in population-based case probands for calculating penetrance.

Pharoah PD, Antoniou A, Hopper J, Easton D.

J Natl Cancer Inst. 2003 Jan 1;95(1):75-6; author reply 77-8. No abstract available.

PMID:
12509407
18.

Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen Cuningham Consortium for Research in Familial Breast Cancer..

Breast Cancer Res. 2006;8(1):R12. Epub 2006 Feb 13.

19.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
20.

Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.

Bonadona V, Sinilnikova OM, Chopin S, Antoniou AC, Mignotte H, Mathevet P, Brémond A, Martin A, Bobin JY, Romestaing P, Raudrant D, Rudigoz RC, Léoné M, Chauvin F, Easton DF, Lenoir GM, Lasset C.

Genes Chromosomes Cancer. 2005 Aug;43(4):404-13.

PMID:
15887246

Supplemental Content

Support Center